Dyadin Esharif
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Dyadin Esharif has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Jason M. Shapiro
Division of Pediatric Gastroenterology, Nutrition and Liver Diseases Hasbro Children's Hospital of Rhode Island Hospital Providence Rhode Island USA
1 shared publication - Michael Herzlinger
Division of Pediatric Gastroenterology, Nutrition and Liver Diseases, Hasbro Children's Hospital and Department of Pediatrics, Warren Alpert Medical School of Brown University, Providence, RI, USA
1 shared publication - Muhammad Safwan Riaz
Division of Pediatric Gastroenterology, Nutrition and Liver Diseases, Hasbro Children's Hospital and Department of Pediatrics, Warren Alpert Medical School of Brown University, Providence, RI, USA
1 shared publication - Phinnara Has
Lifespan Biostatistics, Epidemiology and Research Design, Rhode Island Hospital, Providence, RI 02903, USA
1 shared publication - Rahiya Rehman
Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics Saint Louis University School of Medicine St. Louis Missouri USA
1 shared publication - Shova Subedi
Warren Alpert Medical School of Brown University, Hasbro Children’s Hospital , Providence, RI
1 shared publication
Latest Publications
- Open Access
- 31 July 2024
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 22 (3) , 351-356
Ustekinumab for anti-tumor necrosis factor refractory pediatric ulcerative colitis: a promising approach towards endoscopic healing
Background/Aims: To describe the role of ustekinumab in inducing remission and endoscopic healing in anti-tumor necrosis factor α nonresponsive pediatric ulcerative colitis patients at a tertiary care inflammatory bowel disease center. Methods: A retrospective chart review was performed on patients with ulcerative colitis receiving ustekinumab. Primary outcome was steroidfree clinical remission at follow-up. Secondary outcomes were biochemical remission and endoscopic healing. Results: Ten children were analyzed; 7 (70%) had ulcerative colitis, and 3 (30%) had inflammatory bowel disease unspecified with colitis. Median follow-up period was 56 weeks. Nine patients (90%) achieved steroid-free clinical remission and biochemical remission. Seven patients had follow-up colonoscopies, out of which 6 (86%) achieved endoscopic remission, while 1 (14%) underwent colectomy. Out of the 3 patients without a follow-up colonoscopy, fecal calprotectin levels downtrended to < 150 mg/kg in 2 patients and < 400 mg/kg in 1 patient from baseline level of > 2,000 mg/kg. Conclusions: Ustekinumab appears efficacious in achieving not only clinical and biochemical remission but also has promising role in inducing endoscopic healing end point in patients who fail other biologics.
- 31 July 2024
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 22 (3) , 351-356
Open AccessUstekinumab for anti-tumor necrosis factor refractory pediatric ulcerative colitis: a promising approach towards endoscopic healing
Background/Aims: To describe the role of ustekinumab in inducing remission and endoscopic healing in anti-tumor necrosis factor α nonresponsive pediatric ulcerative colitis patients at a tertiary care inflammatory bowel disease center. Methods: A retrospective chart review was performed on patients with ulcerative colitis receiving ustekinumab. Primary outcome was steroidfree clinical remission at follow-up. Secondary outcomes were biochemical remission and endoscopic healing. Results: Ten children were analyzed; 7 (70%) had ulcerative colitis, and 3 (30%) had inflammatory bowel disease unspecified with colitis. Median follow-up period was 56 weeks. Nine patients (90%) achieved steroid-free clinical remission and biochemical remission. Seven patients had follow-up colonoscopies, out of which 6 (86%) achieved endoscopic remission, while 1 (14%) underwent colectomy. Out of the 3 patients without a follow-up colonoscopy, fecal calprotectin levels downtrended to < 150 mg/kg in 2 patients and < 400 mg/kg in 1 patient from baseline level of > 2,000 mg/kg. Conclusions: Ustekinumab appears efficacious in achieving not only clinical and biochemical remission but also has promising role in inducing endoscopic healing end point in patients who fail other biologics.